A new partnership between Walmart and drug maker Eli Lily will make it easier for people to access the super-popular weight loss drug Zepbound.

These growth stocks are highly profitable and evolving in their respective industries. Eli Lilly is famed for its weight-loss medications, but it is more than just a GLP-1 play. MercadoLibre is a ...

Wall Street rallied higher as investors digested upbeat earnings from big tech companies during the week. The Nasdaq gained 2 ...

Eli Lilly is partnering with Walmart to offer Zepbound through its direct-to-consumer program, making the popular medication ...

Eli Lilly delivered a stunning financial performance that exceeded even the most optimistic market expectations, driven by unprecedented demand for its ...

el agonista del GLP-1 de Eli Lilly comercializado como Mounjaro para el tratamiento de la diabetes y Zepbound para la pérdida de peso, afecta los síntomas durante un período de 12 meses. «Se ha ...

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and fueling a bidding war over another drugmaker.

Health-care companies rose amid earnings optimism. Eli Lilly added to gains, amid a sense that the maker of Mounjaro and Zepbound is pulling away from its competition in the obesity-drug boom.

Wegovy Zepbound cost-effectiveness report finds both drugs remain valuable at higher prices despite affordability concerns, per ICER analysis.

Pharmaceutical titan Eli Lilly has delivered a quarterly report that dramatically surpassed market forecasts, sending waves ...

This proprietary system employs specialized algorithms to identify early signs of litigation trends in federal litigation filings. Click here to learn more about Law.com Radar's new suit alerting and ...

Eli Lilly LLY reported 54% revenue growth in the third quarter as its diabetes and obesity drug tirzepatide ...